ARS Pharmaceuticals Management
Management criteria checks 2/4
ARS Pharmaceuticals' CEO is Rich Lowenthal, appointed in Nov 2022, has a tenure of 2.17 years. total yearly compensation is $10.04M, comprised of 6.2% salary and 93.8% bonuses, including company stock and options. directly owns 5.74% of the company’s shares, worth $61.76M. The average tenure of the management team and the board of directors is 2.8 years and 3.4 years respectively.
Key information
Rich Lowenthal
Chief executive officer
US$10.0m
Total compensation
| CEO salary percentage | 6.2% |
| CEO tenure | 2.2yrs |
| CEO ownership | 5.7% |
| Management average tenure | 2.8yrs |
| Board average tenure | 3.4yrs |
Recent management updates
Recent updates
ARS Pharmaceuticals: Demand Curve Is Key Unknown
Nov 20We're Interested To See How ARS Pharmaceuticals (NASDAQ:SPRY) Uses Its Cash Hoard To Grow
Sep 13
ARS Pharmaceuticals: A Decent Bet For Upside After Neffy Approval
Sep 06ARS Pharmaceuticals On Track With Neffy Despite Regulatory Hurdles
Jun 25We're Not Very Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Rate
Mar 18ARS Pharmaceuticals (NASDAQ:SPRY) Is In A Good Position To Deliver On Growth Plans
Nov 14Here's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation
May 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$49m |
| Jun 30 2024 | n/a | n/a | -US$45m |
| Mar 31 2024 | n/a | n/a | -US$50m |
| Dec 31 2023 | US$10m | US$620k | -US$54m |
| Sep 30 2023 | n/a | n/a | -US$62m |
| Jun 30 2023 | n/a | n/a | -US$53m |
| Mar 31 2023 | n/a | n/a | -US$42m |
| Dec 31 2022 | US$909k | US$75k | -US$35m |
Compensation vs Market: Rich's total compensation ($USD10.04M) is above average for companies of similar size in the US market ($USD3.21M).
Compensation vs Earnings: Rich's compensation has increased whilst the company is unprofitable.
CEO
Rich Lowenthal (58 yo)
2.2yrs
Tenure
US$10,039,096
Compensation
Mr. Richard E. Lowenthal, also known as Rich, MS, MSEL, MBA, He serves as Director, Chief Executive Officer & President at ARS Pharmaceuticals, Inc. since November 08, 2022. He served as Head of Regulatory...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 2.2yrs | US$10.04m | 5.74% $ 61.8m | |
| Co-Founder & Chief Medical Officer | no data | US$4.79m | 3.53% $ 38.0m | |
| Chief Legal Officer & Secretary | 2yrs | US$5.32m | 0.092% $ 988.6k | |
| Co-Founder & Chief Science Officer | no data | no data | 4.34% $ 46.7m | |
| Chief Financial Officer | 2.8yrs | no data | 0.014% $ 146.2k | |
| Chief Operations Officer | no data | no data | 0.0062% $ 66.8k | |
| Senior Vice President of Marketing | 2.9yrs | no data | no data | |
| Executive Vice President of Commercial Strategy | 2.9yrs | no data | no data | |
| Chief Commercial Officer | 2.8yrs | US$618.61k | 0.0059% $ 63.1k | |
| Chief Business Officer & Secretary | 2.2yrs | no data | 0.14% $ 1.5m |
2.8yrs
Average Tenure
55yo
Average Age
Experienced Management: SPRY's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 2.2yrs | US$10.04m | 5.74% $ 61.8m | |
| Independent Director | no data | US$261.30k | 0% $ 0 | |
| Chairman of the Board | no data | US$508.80k | 4.96% $ 53.5m | |
| Director | 3.7yrs | US$238.80k | 0% $ 0 | |
| Independent Director | 3.4yrs | US$256.30k | no data | |
| Independent Director | 3.4yrs | US$253.80k | no data | |
| Independent Director | 2.2yrs | US$250.05k | 0.016% $ 168.8k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | no data | US$248.80k | 0.086% $ 922.2k | |
| Member of Scientific Advisory Board | no data | no data | no data |
3.4yrs
Average Tenure
54yo
Average Age
Experienced Board: SPRY's board of directors are considered experienced (3.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/07 00:05 |
| End of Day Share Price | 2025/01/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ARS Pharmaceuticals, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joshua Schimmer | Cantor Fitzgerald & Co. |
| Roanna Clarissa Ruiz | Leerink Partners LLC |
| Ryan Deschner | Raymond James & Associates |